http://www.reactome.org/bio... | rdf:type | biopax3:BiochemicalReaction | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:comment | Edited: Rothfels, K, 2012-05-16 | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:comment | Reviewed: Ezzat, S, 2012-05-15 | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:comment | Authored: Rothfels, K, 2012-02-09 | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:comment | FP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011). | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:xref | urn:biopax:UnificationXref:... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:xref | urn:biopax:UnificationXref:... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:dataSource | urn:biopax:Provenance:react... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:dataSource | http://www.reactome.org/bio... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:displayName | FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:left | http://www.reactome.org/bio... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:left | http://www.reactome.org/bio... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:right | http://www.reactome.org/bio... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:stepProcess | http://www.reactome.org/bio... | lld:biopax3 |
http://www.reactome.org/bio... | biopax3:pathwayComponent | http://www.reactome.org/bio... | lld:biopax3 |